PACS Group (NYSE:PACS) Given New $67.00 Price Target at UBS Group

Key Points

• UBS raised its PACS Group price target to $67 from $60 and maintained a Buy rating, implying about 34% upside from the cited share price.
• Analyst sentiment is broadly positive: six analysts rate the stock Buy and two Hold, with a consensus target of $61.33.
• PACS beat quarterly estimates, reporting EPS of $0.63 versus $0.58 expected and revenue of $1.50 billion versus $1.46 billion expected.

PACS Group (NYSE:PACS - Get Free Report) had its target price raised by equities research analysts at UBS Group from $60.00 to $67.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's price objective would suggest a potential upside of 33.93% from the stock's current price.

PACS has been the subject of a number of other research reports. JPMorgan Chase & Co. lifted their price objective on PACS Group from $47.00 to $58.00 and gave the company an "overweight" rating in a research report on Friday, September 4th. Wall Street Zen lowered PACS Group from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Stephens raised their price target on PACS Group from $60.00 to $64.00 and gave the stock an "overweight" rating in a research note on Thursday. Oppenheimer raised their price target on PACS Group from $48.00 to $57.00 and gave the stock an "outperform" rating in a research note on Monday, August 10th. Finally, Royal Bank Of Canada lifted their price target on PACS Group from $52.00 to $57.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $61.33.

PACS Group Stock Down 0.5%

Shares of NYSE:PACS traded down $0.23 during trading on Thursday, reaching $50.03. 1,563,269 shares of the company traded hands, compared to its average volume of 899,129. The firm has a fifty day simple moving average of $44.53 and a 200 day simple moving average of $39.96. The firm has a market cap of $7.92 billion, a P/E ratio of 28.26, a price-to-earnings-growth ratio of 1.46 and a beta of -0.14. PACS Group has a 1-year low of $10.31 and a 1-year high of $51.68. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.21.

PACS Group (NYSE:PACS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.58 by $0.05. PACS Group had a net margin of 4.87% and a return on equity of 33.39%. The business had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.46 billion. Analysts anticipate that PACS Group will post 2.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other PACS Group news, CAO Michelle Lewis sold 3,172 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $50.06, for a total transaction of $158,790.32. Following the transaction, the chief accounting officer directly owned 340,338 shares of the company's stock, valued at $17,037,320.28. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Hancock sold 186,696 shares of the firm's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $50.45, for a total value of $9,418,813.20. Following the transaction, the director owned 53,318,884 shares in the company, valued at approximately $2,689,937,697.80. This trade represents a 0.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,762,431 shares of company stock worth $80,686,053. Corporate insiders own 70.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PACS. Dimensional Fund Advisors LP lifted its holdings in PACS Group by 370.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 780,159 shares of the company's stock worth $25,051,000 after purchasing an additional 614,250 shares during the last quarter. Sei Investments Co. boosted its position in PACS Group by 7.4% during the first quarter. Sei Investments Co. now owns 370,501 shares of the company's stock worth $11,900,000 after purchasing an additional 25,462 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in PACS Group by 44.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 288,718 shares of the company's stock worth $9,274,000 after purchasing an additional 89,067 shares during the period. Bank of New York Mellon Corp acquired a new position in PACS Group during the second quarter valued at approximately $8,196,000. Finally, Corient Private Wealth LP grew its holdings in PACS Group by 1.8% during the second quarter. Corient Private Wealth LP now owns 152,846 shares of the company's stock valued at $6,517,000 after purchasing an additional 2,680 shares during the last quarter.

Trending Headlines about PACS Group

Here are the key news stories impacting PACS Group this week:

• Positive Sentiment: Third-quarter EPS of $0.63 topped estimates of $0.58, while revenue of $1.50 billion exceeded the $1.46 billion consensus. Adjusted EBITDA reportedly rose 33.6%, reinforcing evidence of operating growth. PACS Group, Inc. Reports Third Quarter 2026 Results PACS Group Q3 2026: EBITDA Surges 33.6%
• Positive Sentiment: PACS raised its 2026 revenue outlook to $5.95 billion–$6.05 billion and adjusted EBITDA guidance to $685 million–$695 million. The company also highlighted acquisitions in Florida and Texas and facility occupancy around 90%, supporting its expansion story. PACS raises 2026 outlook PACS acquisitions and Q3 results
• Positive Sentiment: Truist reaffirmed its Buy rating and raised its target to $65 from $62; Stephens raised its target to $64 from $60 and assigned an Overweight rating. Higher targets signal continued analyst confidence in potential upside. Truist analyst ratings Stephens analyst ratings
• Negative Sentiment: The CEO, a director, and the chief accounting officer reported share sales. These could weigh slightly on sentiment, but the trades were made under pre-arranged Rule 10b5-1 plans, and the CEO and director retained large holdings. PACS insider transactions

About PACS Group

PACS Group, Inc is a U.S.-based healthcare services company that owns and operates post-acute care facilities. Its platform focuses primarily on skilled nursing and transitional care, serving patients who require rehabilitation, recovery support, long-term care, and other services following hospitalization or acute medical treatment.

The company's operations also include assisted living, independent living, and behavioral health services in select locations. Through its facilities and related healthcare capabilities, PACS Group provides services such as nursing care, physical and occupational therapy, speech therapy, medical treatment, and support for patients with complex or extended care needs.

Founded in 2013 and headquartered in Farmington, Utah, PACS Group serves communities across multiple U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.